Kanada - angličtina - Health Canada

auro pharma inc - efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet - 600mg; 200mg; 300mg - efavirenz 600mg; emtricitabine 200mg; tenofovir disoproxil fumarate 300mg - nonnucleoside reverse transcriptase inhibitors

Kanada - angličtina - Health Canada

pharmascience inc - efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet - 600mg; 200mg; 300mg - efavirenz 600mg; emtricitabine 200mg; tenofovir disoproxil fumarate 300mg - nonnucleoside reverse transcriptase inhibitors

Kanada - angličtina - Health Canada

sandoz canada incorporated - efavirenz; emtricitabine; tenofovir disoproxil fumarate - tablet - 600mg; 200mg; 300mg - efavirenz 600mg; emtricitabine 200mg; tenofovir disoproxil fumarate 300mg - nonnucleoside reverse transcriptase inhibitors

Kanada - angličtina - Health Canada

sanofi consumer health inc - fexofenadine hydrochloride - tablet - 60mg - fexofenadine hydrochloride 60mg - second generation antihistamines

Austrália - angličtina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adama australia pty limited - terbuthylazine - water dispersible granule - terbuthylazine triazine active 800.0 g/kg - herbicide

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 120mg;  ;   - film coated tablet - 120 mg - active: fexofenadine hydrochloride 120mg     excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 180mg;  ;   - film coated tablet - 180 mg - active: fexofenadine hydrochloride 180mg     excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 30mg;   - film coated tablet - 30 mg - active: fexofenadine hydrochloride 30mg   excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 60mg;  ;   - film coated tablet - 60 mg - active: fexofenadine hydrochloride 60mg     excipient: colloidal silicon dioxide croscarmellose sodium ferric oxide, pink hypromellose e-15 hypromellose e-5 iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose povidone pregelatinised maize starch titanium dioxide - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Spojené štáty - angličtina - NLM (National Library of Medicine)

viiv healthcare company - delavirdine mesylate (unii: 421105krqe) (delavirdine - unii:dol5f9jd3e) - delavirdine mesylate 100 mg - rescriptor tablets are indicated for the treatment of hiv-1 infection in combination with at least 2 other active antiretroviral agents when therapy is warranted. the following should be considered before initiating therapy with rescriptor in treatment-naive patients. there are insufficient data directly comparing antiretroviral regimens containing rescriptor with currently preferred 3-drug regimens for initial treatment of hiv. in studies comparing regimens consisting of 2 nucleoside reverse transcriptase inhibitors (nrtis) (currently considered suboptimal) to rescriptor plus 2 nrtis, the proportion of patients receiving the regimen containing rescriptor who achieved and sustained an hiv-1 rna level <400 copies/ml over 1 year of therapy was relatively low (see description of clinical studies). resistant virus emerges rapidly when rescriptor is administered as monotherapy. therefore, rescriptor should always be administered in combination with other antiretroviral agents. rescriptor tablets are contraindicate